Page 107 - Read Online
P. 107

Page 6 of 7                                                       Sen. Hepatoma Res 2018;4:37  I  http://dx.doi.org/10.20517/2394-5079.2018.39


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.

               Conflicts of interest
               The author declares that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2018.


               REFERENCES
               1.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
               2.   El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
               3.   Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
               4.   Zucman-Rossi J, Laurent-Puig P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies.
                   Pharmacogenomics 2007;8:997-1003.
               5.   Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 2012;18:472-82.
               6.   Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in
                   human tissue transcriptomes. Nature 2008;456:470-6.
               7.   Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-
                   throughput sequencing. Nat Genet 2008;40:1413-5.
               8.   Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, Sun S, Yang F, Shen YA, Murray RR, Spirohn K, Begg
                   BE, Duran-Frigola M, MacWilliams A, Pevzner SJ, Zhong Q, Trigg SA, Tam S, Ghamsari L, Sahni N, Yi S, Rodriguez MD, Balcha D, Tan
                   G, Costanzo M, Andrews B, Boone C, Zhou XJ, Salehi-Ashtiani K, Charloteaux B, Chen AA, Calderwood MA, Aloy P, Roth FP, Hill DE,
                   Iakoucheva LM, Xia Y, Vidal M. Widespread expansion of protein interaction capabilities by alternative splicing. Cell 2016;164:805-17.
               9.   Chabot B. Directing alternative splicing: cast and scenarios. Trends Genet 1996;12:472-8.
               10.  Lee Y, Rio DC. Mechanisms and regulation of alternative pre-mRNA splicing. Annu Rev Biochem 2015;84:291-323.
               11.  Barreau C, Paillard L, Mereau A, Osborne HB. Mammalian CELF/Bruno-like RNA-binding proteins: molecular characteristics and
                   biological functions. Biochimie 2006;88:515-25.
               12.  Sutherland LC, Rintala-Maki ND, White RD, Morin CD. RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J
                   Cell Biochem 2005;94:5-24.
               13.  David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010;24:2343-64.
               14.  Dominguez D, Tsai YH, Weatheritt R, Wang Y, Blencowe BJ, Wang Z. An extensive program of periodic alternative splicing linked to cell
                   cycle progression. Elife 2016;5.
               15.  Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene 2014;33:5311-8.
               16.  Berasain C, Goni S, Castillo J, Latasa MU, Prieto J, Avila MA. Impairment of pre-mRNA splicing in liver disease: mechanisms and
                   consequences. World J Gastroenterol 2010;16:3091-102.
               17.  Zhang L, Liu X, Zhang X, Chen R. Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing
                   events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets. Mol Genet Genomics 2016;291:1035-51.
               18.  Liu XN, Yuan JH, Wang TT, Pan W, Sun SH. An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression. Biomed
                   Pharmacother 2017;89:276-83.
               19.  Lu Y, Xu W, Ji J, Feng D, Sourbier C, Yang Y, Qu J, Zeng Z, Wang C, Chang X, Chen Y, Mishra A, Xu M, Lee MJ, Lee S, Trepel J,
                   Linehan WM, Wang X, Yang Y, Neckers L. Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. Hepatology
                   2015;62:1122-31.
               20.  Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Claperon A, Chretien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C,
                   Rosmorduc O, Desbois-Mouthon C. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-
                   mediated dysregulation of RNA splicing factors. Cancer Res 2013;73:3974-86.
               21.  Zhang J, Ren J, Wei J, Chong CC, Yang D, He Y, Chen GG, Lai PB. Alternative splicing of estrogen receptor alpha in hepatocellular
                   carcinoma. BMC Cancer 2016;16:926.
               22.  Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade,
   102   103   104   105   106   107   108   109   110   111   112